STOCK TITAN

Aditxt Inc - ADTX STOCK NEWS

Welcome to our dedicated news page for Aditxt (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aditxt's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aditxt's position in the market.

Rhea-AI Summary
Aditxt, Inc. (NASDAQ: ADTX) closed a private placement offering, raising $6 million in gross proceeds. The company sold 1,237,114 shares of common stock at a purchase price of $4.85 per share and accompanying warrants. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
-
Rhea-AI Summary
Aditxt, Inc. (NASDAQ: ADTX) regains compliance with Nasdaq's minimum stockholders' equity requirement, ensuring future growth and innovation. The company is dedicated to accelerating innovation in autoimmunity, health by the numbers, transplantation, population health, and women's health, including the recently announced Evofem transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.6%
Tags
none
-
Rhea-AI Summary
Aditxt, Inc. (NASDAQ: ADTX) has entered into definitive agreements for the purchase and sale of 1,237,114 shares of common stock at a purchase price of $4.85 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Evofem Biosciences, Inc. (EVFM) and Aditxt, Inc. (ADTX) have announced a definitive agreement for Aditxt to acquire Evofem in a transaction valued at approximately $100 million. Evofem, the creator of the FDA-approved hormone-free contraceptive gel, Phexxi®, has posted $13.4 million in net sales for the first nine months of 2023. Aditxt aims to accelerate Evofem into the global non-hormonal birth control market, projected to grow from $27.7 billion in 2022 to $52.2 billion by 2031.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.26%
Tags
acquisition
-
Rhea-AI Summary
Evofem Biosciences, Inc. (EVFM) and Aditxt, Inc. (ADTX) have announced a definitive agreement for Aditxt to acquire Evofem in a transaction valued at approximately $100 million. Evofem, the creator of the FDA-approved hormone-free contraceptive gel, Phexxi®, has posted $13.4 million in net sales for the first nine months of 2023. Aditxt aims to accelerate Evofem into the global non-hormonal birth control market, projected to grow from $27.7 billion in 2022 to $52.2 billion by 2031.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.71%
Tags
acquisition
-
Rhea-AI Summary
Aditxt CEO to present at 8th Annual Dawson James Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
conferences
Rhea-AI Summary
Aditxt appoints Ernie Lee as CEO of Pearsanta to accelerate the commercial launch of Test2Treat.me, a clinical diagnostic testing services platform for healthcare providers and consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
management
-
Rhea-AI Summary
Aditxt CEO to deliver company presentation at H.C. Wainwright Global Investment Conference on September 13th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Summary
Aditxt, Inc. closes private placement, raising $10.0 million for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.68%
Tags
none
Rhea-AI Summary
Aditxt announces private placement offering of 1,000,000 shares of common stock at $10.00 per share, expected to raise $10.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.8%
Tags
none
Aditxt Inc

Nasdaq:ADTX

ADTX Rankings

ADTX Stock Data

5.06M
433.89k
9.43%
6.06%
1.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Richmond

About ADTX

a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.